A sterile dry-cow intramammary suspension of benzathine cloxacillin is processed as an aseptic oil dispersion rather than an aqueous solution. The benzathine salt is selected because its low aqueous solubility slows dissolution in the udder after single-dose administration. A representative veterinary presentation contains 500 mg of cloxacillin activity per 10 mL syringe, but the exact dose is defined by the authorised label. The API is milled under low-humidity air in a jet mill or pin mill. Particle-size distribution is controlled by laser diffraction using Ph. Eur. 2.9.31 or USP <429>. The target D90 is manufacturer-specific. Particles below 10 µm increase surface area and oil-phase viscosity, while particles above 150 µm may obstruct the intramammary cannula and produce uneven udder distribution. The vehicle consists of white mineral oil gelled with aluminium stearate at 0.5–2.0% w/w. Sorbitan monooleate or a comparable non-ionic wetting agent is incorporated at 0.5–2.0% w/w to reduce oil–particle interfacial tension. The suspension is prepared under vacuum in a planetary mixer to prevent air entrainment. Viscosity is measured at 20 °C with a rotational viscometer. Formulations exceeding 500 mPa·s require excessive extrusion force from the prefilled syringe. Aseptic filling is performed on a multichannel filling line using pre-sterilised high-density polyethylene intramammary syringes. Sterility is confirmed by membrane filtration according to Ph. Eur. 2.6.1. Bacterial endotoxin release is controlled using Ph. Eur. 2.6.14. Water content is maintained below 0.2% w/w by Karl Fischer titration Ph. Eur. 2.5.12. Free water accelerates beta-lactam hydrolysis and destabilises the gelled oil structure. Terminal steam sterilisation is avoided because of beta-lactam thermal lability and poor heat penetration in viscous oil suspensions.

Redispersion failure is a known production-scale problem. Temperature cycling between 5 °C and 40 °C can cause sediment caking in the syringe barrel. The thixotropic vehicle must rebuild structure after shaking without immobilising the settled drug. In-use tests measure the number of syringe inversions required to achieve uniform opacity. Milk residue behaviour is governed by regional residue-depletion data. In the EU, the maximum residue limit for cloxacillin in bovine milk is 30 µg/kg under Commission Regulation (EU) No 37/2010. The terminal finished product is a pre-filled single-dose intramammary syringe for dry-cow therapy.

What Limits Benzathine Cloxacillin Use in Lactating-Cow Intramammary Infusions?

The use of benzathine cloxacillin in lactating-cow intramammary infusions is constrained by prolonged udder residence and milk withholding economics. Milk is harvested twice daily. A slow-release benzathine depot may extend the period during which milk must be withheld. The formulator may combine a smaller proportion of benzathine cloxacillin with a faster-release salt such as cloxacillin sodium, but the ratio is not fixed in public monographs and must be justified by residue depletion studies. Processing remains aseptic and oil based, but the vehicle is usually less viscous than in dry-cow preparations. The filling equipment and sterility test are equivalent to those used for dry-cow syringes. The terminal product is a single-dose intramammary syringe intended for lactating cows. In the EU, the withdrawal period is fixed in the marketing authorisation under Regulation (EU) 2019/6. The benzathine salt is often limited to a minor component or omitted entirely because cloxacillin sodium provides a more predictable milking withholding profile in lactating animals.

When Parenteral Injection Rather than Intramammary Infusion Is Required

For a parenteral veterinary injection, benzathine cloxacillin is formulated as a wet-milled aqueous or oil suspension rather than as a reconstituted solution. Intravenous administration is contraindicated because of the particulate state and low aqueous solubility of the benzathine salt. The slurry is prepared by dispersing the API in water containing polysorbate 80 and a suspending agent such as sodium carboxymethylcellulose. High-shear homogenisation breaks loose agglomerates. Particle-size distribution is measured by laser diffraction in accordance with USP <429> or Ph. Eur. 2.9.31. Subvisible particulate matter is checked by USP <788> or Ph. Eur. 2.9.19. Syringeability is evaluated through 18G to 21G needles using a universal testing machine to measure extrusion force. The suspension is filled aseptically into pre-sterilised vials under a nitrogen overlay. Sterility testing follows Ph. Eur. 2.6.1 or USP <71>. Compatibility with aminoglycosides must not be assumed. Beta-lactam antibiotics can inactivate aminoglycoside antibiotics when mixed in the same vehicle. Published systemic pharmacokinetic data for benzathine cloxacillin injection in food-producing species is limited. The formulation is therefore developed only after a target-animal residue and local tolerability programme is completed. The terminal product is a ready-to-use parenteral suspension for intramuscular or subcutaneous administration when specifically authorised. It is not an intravenous solution.

Compression of benzathine cloxacillin into veterinary tablets or oral boluses is based on dry granulation because the benzathine salt is hydrophobic and water-sensitive. Roller compaction is preferred over wet granulation. The API is preblended with microcrystalline cellulose, lactose monohydrate, crospovidone, and a lubricant such as magnesium stearate or sodium stearyl fumarate. Disintegrant content is typically set in the 2–5% w/w range. Lubricant content is kept below 1.0% w/w to avoid excessive dissolution delay. The roller compactor is operated under low-humidity air to prevent sticking. Ribbons are milled through an oscillating mill fitted with a 0.8–1.2 mm screen. The milled compact is blended again and compressed on a rotary tablet press with precompression. Tablet hardness is adjusted to balance mechanical strength against disintegration. Loss on drying is maintained below 2.0% w/w by USP <731>. Dissolution is measured by USP <711> apparatus 2 at 50 rpm in phosphate buffer pH 6.8. Because the benzathine salt has low aqueous solubility, the dissolution method may require a non-ionic surfactant. A globally standard acceptance criterion does not exist. The limit must be developed from the authorised formulation and validated against an in-house reference lot. Tablet friability is tested by USP <1216>. The finished tablet or bolus is an oral dosage form for veterinary patients when susceptibility testing under CLSI VET01S supports cloxacillin use.

Hard Capsule Powder Filling and Controlled-Humidity Handling

When hard capsule filling is selected for benzathine cloxacillin, the operation is constrained by powder flow and moisture. The API is blended with silicified microcrystalline cellulose and crospovidone. The target blend has a Carr index below 25 when tested by USP <1174>. Higher values cause powder bridging in dosator nozzles and mass-variation faults on intermittent-motion capsule machines. Gelatin capsules are processed in a room held at 40–50% RH. Weight uniformity is tested by Ph. Eur. 2.9.5 or USP <905>. Disintegration is confirmed by USP <701>. Water activity is controlled below 0.6 using the procedure described in USP <1112>. Encapsulated powders above this threshold can soften gelatin shells and accelerate beta-lactam hydrolysis. Empty capsule shells are stored under low-humidity conditions to prevent embrittlement. The terminal product is a hard capsule containing declared cloxacillin activity for oral use in companion animals or calves under veterinary prescription. Published product-specific dissolution tests for benzathine cloxacillin capsules are limited. A justified in-house test is required.

In low-shear oral powder production, the API is blended with anhydrous lactose or dextrose in a V-blender or bin blender. Blend homogeneity is verified by sampling at 10 separate points with a target relative standard deviation below 5.0%. The mixed powder is filled into moisture-barrier sachets by a volumetric auger filler. The sachet headspace is flushed with nitrogen to limit oxidative and moisture-driven degradation. The finished oral powder may be top-dressed onto feed or reconstituted with water at the point of use. Reconstitution does not produce a true solution because the benzathine salt remains particulate. The label must instruct vigorous shaking. A D90 below 150 µm is normally maintained to prevent settling and dose variation. The terminal product is an oral powder for veterinary administration.

Achieving Low-Moisture Granulation in a Top-Spray Fluid Bed

Granulation of benzathine cloxacillin in a top-spray fluid bed requires a binder system that minimises water exposure. Ethanol or isopropanol with a small amount of dissolved binder is used instead of a plain aqueous binder. The fluid bed is run at an inlet air temperature of 40–60 °C and a product temperature of 28–35 °C. The dew point of the fluidising air is held below 5 °C to reduce hydrolytic load. Spray rate is adjusted so that bed moisture does not cause defluidisation or particle collapse. After granulation, the product is dried until residual ethanol or isopropanol meets the requirements of VICH GL 18 and USP <467>. The dried granules are screened to a target of 0.3–0.8 mm. Fines below 75 µm are limited because they reduce flow and create dust during filling. The granules are filled into bottles with a scoop or into unit-dose sachets. Particle-size distribution after reconstitution is measured by Ph. Eur. 2.9.31. The terminal finished form is an oral granule for veterinary patients. It is a suspension-forming granular product rather than an immediate-release solution.

Technically, medicated feed premix and aqueous solution formats present opposite constraints for benzathine cloxacillin. The benzathine salt cannot form a true aqueous solution at practical dose volumes. A solution product therefore requires cloxacillin sodium or potassium, not the benzathine salt. A benzathine-based liquid would be a suspension and needs suspending agents and shake-before-use instructions. Feed premix is possible only when the manufacturing line avoids prolonged steam conditioning. Pelleting temperatures of 70–85 °C are common in feed plants and accelerate beta-lactam ring degradation. Premix preparation is therefore limited to meal-feed addition or post-pelleting mixing. Homogeneity of the premix is verified by a validated sampling plan. The coefficient of variation is set by the manufacturer and local feed-control requirements. Published commercial premix and oral solution examples based on this specific salt are limited. The finished premix, if produced, is a bulk powder intermediate for dilution at the feed mill, not a directly administerable product.